The use of PEG-Hirudin in chronic hemodialysis monitored by the Ecarin Clotting Time: Influence on clotting of the extracorporeal system and hemostatic parameters

Clinical Nephrology

Volumn 65, Issue 3, 2006, Pages 180-190

  Ulbricht, Kristina ^a   Bucha, E ^b   Poschel K A ^a   Stein, G ^a   Wolf, G ^a   Nowak, G ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b HaemoSys GmbH   (Germany)

Author keywords

Blood coagulation; Ecarin clotting time; Hemodialysis; PEG Hirudin; Soluble fibrin

Indexed keywords

ANTITHROMBIN III; ECARIN; FIBRIN; FIBRINOGEN; HEPARIN; HIRUDIN; PLACEBO; POLYETHYLENE GLYCOL HIRUDIN; PROTHROMBIN; SODIUM CHLORIDE; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG USE; EXTRACORPOREAL CIRCULATION; FEMALE; FREQUENCY ANALYSIS; HEMODIALYSIS; HEMOSTASIS; HUMAN; LONG TERM CARE; MALE; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSITIVITY ANALYSIS; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 33644747187     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP65180     Document Type: Article

References (23)

1. Alexander B, Burnard KG, Lattimer CL, Humphries J, Gaffney PJ, Eastham D, Smith A 2004 The effect of anticoagulation with subcutaneously delivered polyethylene glycol conjugated hirudin and recombinant tissue plasminogen activator on recurrent stenosis in the rabbit double-balloon injury model. Thromb Res 113: 155-161
2. Bucha E, Kreml R, Nowak G 1999 In vitro study of r-Hirudin permeability through membranes of different haemodialyzers. Nephrol Dial Transplant 14: 2922-2926
3. Bucha E, Nowak G, Czerwinski R, Thieler H 1999 R-Hirudin as anticoagulant in regular hemodialysis therapy: finding of therapeutic r-hirudin blood/ plasma concentrations and respective dosages. Clin Appl Thrombosis Hemostasis 5: 164-170
4. Esslinger HU, Haas S, Maurer R, Lassmann A, Dübbers K, Müller-Peltzer H 1997 Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers. Thromb Haemost 77: 911-919
5. Fuster V, Badimon L, Badimon JJ, Chesebro JH 1992 The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326: 310-318
6. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Potzsch B 1999 Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99: 73-80
7. Glusa E 1991 Blutplättchen und Hirudin. Hämostaseologie 11: 163-166
8. Glusa E 1998 Pharmacology and therapeutic applications of hirudin, a new anticoagulant. Kidney Int 53 (Suppl 64): 54-64
9. Hoffmann JJM, Janssen WC 2001 Comparison of three methods for measuring PEG-hirudin in blood. Blood Coagul Fibrinolysis 12: 577-581
10. Koide M, Yamamoto S, Matsuo M, Suzuki S, Arima N, Matsuo T 1995 Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 10: 2137-2140
11. Moser M, Ruef J, Per KH, Kohler B, Gulba DC, Paterna N, Nordt T, Kübler W, Bode C 2001 Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity. J Thrombosis Thrombolysis 12: 165-169
12. Nowak G, Bucha E 1996 Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 22.: 197-202
13. Nowak G, Bucha E, Brauns I, Czerwinski R 1997 Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia: The first long term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 109: 354-358
14. Nowak G 2001 Hirudin in der vaskulären Medizin, edited by Greinacher A, Uni-Med, Bremen, pp 20-36
15. Nowak G, Bucha E 2002 Toxic blood levels of PEG-Hirudin can be antagonized by PMMA dialyzers in vivo. Ann Hematol 81 (Suppl 1): A 59
16. Pöschel K, Bucha E, Esslinger HU, Nörtersheuser P, Jansa U, Schindler S, Nowak G, Stein G 2000 Pharmacodynamics and pharmacokinetics of polyethyleneglycol-hirudin in patients with chronic renal failure. Kidney Int 58: 2478-2484
17. Pöschel K, Bucha E, Esslinger HU, Ulbricht K, Nörtershäuser P, Stein G, Nowak G 2004 Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. Kidney Int 65: 666-674
18. Rübsamen K, Hornberger W 1996 Prevention of early reocclusion after thrombolysis of copper coil-induced thrombin in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin. Thromb Haemost 76: 105-110
19. Sperschneider H, Deppisch R, Beck W, Wolf H, Stein G 1997 Impact of membrane choice and blood flow pattern on coagulation and heparin requirement - potential consequences on lipid concentrations. Nephrol Dial Transplant 12: 2683-2646
20. Sperschneider 1999 Heparine bei extrakorporalen Behandlungsverfahren. Spektrum der Nephrologie 6: 3-12
21. Van Wyk V, Badenhorst PN, Luus HG, Kotzé HF 1995 A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 48: 1338-1343
22. Vanholder R, Camez AA, Veys NM, Soria J, Mirshahi M, Soria C, Ringoir S 1994 Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 45: 1754-1759
23. Warkentin TE 1999 Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med 83: 129-147